Cargando…

Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide

Prothionamide (PTH), a second line antitubercular drug is used to administer in conventional oral route. However, its unpredictable absorption and frequent administration limit its use. An alternate approach was thought of administering PTH through pulmonary route in a form of nanoparticles, which c...

Descripción completa

Detalles Bibliográficos
Autores principales: Debnath, Sujit Kumar, Saisivam, Srinivasan, Debanth, Monalisha, Omri, Abdelwahab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784924/
https://www.ncbi.nlm.nih.gov/pubmed/29370192
http://dx.doi.org/10.1371/journal.pone.0190976
_version_ 1783295535681110016
author Debnath, Sujit Kumar
Saisivam, Srinivasan
Debanth, Monalisha
Omri, Abdelwahab
author_facet Debnath, Sujit Kumar
Saisivam, Srinivasan
Debanth, Monalisha
Omri, Abdelwahab
author_sort Debnath, Sujit Kumar
collection PubMed
description Prothionamide (PTH), a second line antitubercular drug is used to administer in conventional oral route. However, its unpredictable absorption and frequent administration limit its use. An alternate approach was thought of administering PTH through pulmonary route in a form of nanoparticles, which can sustain the release for several hours in lungs. Chitosan, a bio-degradable polymer was used to coat PTH and further freeze dried to prepare dry powder inhaler (DPI) with aerodynamic particle size of 1.76μm. In vitro release study showed initial burst release followed by sustained release up to 96.91% in 24h. In vitro release further correlated with in vivo study. Prepared DPI maintained the PTH concentration above MIC for more than 12h after single dose administration and increased the PTH residency in the lungs tissue more than 24h. Animal study also revealed the reduction of dose in pulmonary administration, which will improve the management of tuberculosis.
format Online
Article
Text
id pubmed-5784924
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57849242018-02-09 Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide Debnath, Sujit Kumar Saisivam, Srinivasan Debanth, Monalisha Omri, Abdelwahab PLoS One Research Article Prothionamide (PTH), a second line antitubercular drug is used to administer in conventional oral route. However, its unpredictable absorption and frequent administration limit its use. An alternate approach was thought of administering PTH through pulmonary route in a form of nanoparticles, which can sustain the release for several hours in lungs. Chitosan, a bio-degradable polymer was used to coat PTH and further freeze dried to prepare dry powder inhaler (DPI) with aerodynamic particle size of 1.76μm. In vitro release study showed initial burst release followed by sustained release up to 96.91% in 24h. In vitro release further correlated with in vivo study. Prepared DPI maintained the PTH concentration above MIC for more than 12h after single dose administration and increased the PTH residency in the lungs tissue more than 24h. Animal study also revealed the reduction of dose in pulmonary administration, which will improve the management of tuberculosis. Public Library of Science 2018-01-25 /pmc/articles/PMC5784924/ /pubmed/29370192 http://dx.doi.org/10.1371/journal.pone.0190976 Text en © 2018 Debnath et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Debnath, Sujit Kumar
Saisivam, Srinivasan
Debanth, Monalisha
Omri, Abdelwahab
Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide
title Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide
title_full Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide
title_fullStr Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide
title_full_unstemmed Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide
title_short Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide
title_sort development and evaluation of chitosan nanoparticles based dry powder inhalation formulations of prothionamide
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784924/
https://www.ncbi.nlm.nih.gov/pubmed/29370192
http://dx.doi.org/10.1371/journal.pone.0190976
work_keys_str_mv AT debnathsujitkumar developmentandevaluationofchitosannanoparticlesbaseddrypowderinhalationformulationsofprothionamide
AT saisivamsrinivasan developmentandevaluationofchitosannanoparticlesbaseddrypowderinhalationformulationsofprothionamide
AT debanthmonalisha developmentandevaluationofchitosannanoparticlesbaseddrypowderinhalationformulationsofprothionamide
AT omriabdelwahab developmentandevaluationofchitosannanoparticlesbaseddrypowderinhalationformulationsofprothionamide